Mn. Sillence et al., EFFECTS OF BRL-47672 ON GROWTH, BETA(2)-ADRENOCEPTORS, AND ADENYLYL-CYCLASE ACTIVATION IN FEMALE RATS, American journal of physiology: endocrinology and metabolism, 31(1), 1995, pp. 159-167
The morpholine compound BRL-47672 has a chemical structure similar to
that of clenbuterol and causes similar anabolic effects in rats but ha
s no actions on beta(2)-adrenoceptors in vitro. It has been argued the
refore that beta(2)-adrenoceptors do not mediate the anabolic effects
of this family of compounds. In the present study BRL-47672 was shown
to bind to rat beta(2)-adrenoceptors with low affinity (dissociation c
onstant 16 mu M) relative to clenbuterol (48 nM) and to be a very weak
activator of adenylyl cyclase activity in rat skeletal muscle membran
es in vitro. In contrast, acute administration of the drug to anesthet
ized rats in vivo caused an increase in muscle adenosine 3',5'-cyclic
monophosphate output, and chronic treatment of conscious rats for >6 d
ays caused a significant increase in weight gain (69%) accounted for b
y increased muscle growth. The anabolic effects of BRL-47672 were not
counteracted by daily injections of the drug ICI-118551 (2 mg/day) but
were prevented when the same beta(2)-antagonist was administered in t
he diet (200 mg/kg feed, equivalent to 4.3 mg/day). The beta(1)-adreno
ceptor selective antagonist CGP-20712A fed in the diet (200 mg/kg feed
) failed to attenuate the response to BRL-47672. These results support
the conclusion that BRL-47672 has little direct action on beta(2)-adr
enoceptors but suggest that the compound is metabolized rapidly in viv
o to a potent beta(2)-agonist. Thus the stimulation of muscle growth b
y BRL-47672 is via beta(2)-adrenoceptors, with no contribution to this
response from beta(1)- or beta(3)-adrenoceptor activation.